Product Summary

• Recombined human-mouse chimeric tumor necrosis factor-α monoclonal antibody is the earliest biological agent used in the field of inflammatory bowel disease in China

• Launched in 2021, National Major Scientific and Technological Special Project for “Significant New Drugs Development. The unique freeze-drying and Liquid pharmaceutical Preparations has won international patents

• The third commercialized macromolecular drugs of BioRay after the launch of Anbainuo® and Anjianning® (Adalimumab). A total of 337 patients were included in Phase III clinical studies. Comprehensive evaluation of pharmacokinetics, efficacy and safety